Sign in
Active, not recruitingNo phase

ALTERRA: SAPIEN 3 THV With the Alterra Adaptive Prestent

Key facts

Who runs it
Edwards Lifesciences
Where
Atlanta, Aurora, Charlottesville, Cincinnati, Columbus, Dallas, Houston, Los Angeles, New York, Philadelphia, San Francisco, Seattle, and St Louis, United StatesSee the 14 sites
Trial code
Status
Active, not recruiting
People taking part
86 people enrolled
Started
22 Aug 2017
Expected to end
Jun 2032
Type of study
Interventional, 2 groups
Treatments tested
  • Edwards Alterra Adaptive Prestent with SAPIEN 3 THV
Record updated
20 October 2026

Who can take part

Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 18 criteriaShow less

Who can take part

  • The candidate/candidate's legally authorized representative has been informed of the nature of the study, agrees to its provisions and has provided written informed consent
  • Weight is ≥ 20 kg (44 lbs)
  • RVOT/PV with moderate or greater PR by TTE
  • RVOT/PV proximal and distal landing zone diameter ≥ 27 mm and ≤ 38 mm, and minimum of 35 mm from contractile tissue to lowest pulmonary artery takeoff

Who cannot take part

  • History of or active endocarditis (active treatment with antibiotics) within the past 180 days
  • Need for concomitant atrial septal defect or ventricular septal defect closure or other concomitant interventional procedures other than pulmonary artery or branch pulmonary artery stenting or angioplasty
  • Interventional/surgical procedures within 30 days prior to the Alterra or valve implant procedure
  • Any planned surgical, percutaneous coronary or peripheral procedure to be performed within the 30 day follow-up from the Alterra or valve implant procedure
  • Known hypersensitivity to aspirin or heparin and cannot be treated with other antiplatelet and/or antithrombotic medications
  • Currently participating in an investigational drug or another device study [Note: Trials requiring extended follow up for products that were investigational, but have since become commercially available, are not considered investigational devices.]
  • Active infection requiring current antibiotic therapy (if temporary illness, patient may be a candidate 2 weeks after discontinuation of antibiotics)
  • History of or current intravenous drug use
  • Major or progressive non-cardiac disease resulting in a life expectancy of less than one year
  • Known hypersensitivity to nitinol, cobalt-chromium, nickel or contrast media that cannot be adequately pre-medicated
  • Leukopenia (WBC < 2000 cells/μL), anemia (Hgb < 7 g/dL), thrombocytopenia (platelets < 50,000 cells/μL) or any known blood clotting disorder
  • Positive urine or serum pregnancy test in female patients of child-bearing potential
  • Renal insufficiency (creatinine > 3.0 mg/dL) and/or renal replacement therapy
  • Inappropriate anatomy for introduction and delivery of the Alterra Adaptive Prestent or the SAPIEN 3 THV

Where in United States

  • Emory University & Children's Healthcare of Atlanta (CHOA)Atlanta, United States
  • Children's Hospital ColoradoAurora, United States
  • University of VirginaCharlottesville, United States
  • Cincinnati Children's HospitalCincinnati, United States
  • Nationwide Children's HospitalColumbus, United States
  • Children's Health DallasDallas, United States
  • Texas Children's HospitalHouston, United States
  • Cedars-Sinai Medical CenterLos Angeles, United States
  • University of California, Los AngelesLos Angeles, United States
  • Columbia University Medical CenterNew York, United States
  • Children's Hospital of PhiladelphiaPhiladelphia, United States
  • University of California San FranciscoSan Francisco, United States
  • Seattle Children's HospitalSeattle, United States
  • St. Louis Children's HospitalSt Louis, United States

About the trial

What the trial wants to find out

To demonstrate the safety and effectiveness of the Edwards Alterra Adaptive Prestent in conjunction with the Edwards SAPIEN 3 Transcatheter Heart Valve (THV) System in subjects with a dysfunctional right ventricular outflow tract/pulmonary valve (RVOT/PV) who are indicated for treatment of pulmonary regurgitation (PR).

Read full original descriptionShow less

Following completion of enrollment, subjects will be eligible for enrollment in the continued access phase of the trial.

The 2 groups in the trial

  • TPVR - Main CohortTreatment being tested

    Implantation of Edwards Alterra Adaptive Prestent and Edwards SAPIEN 3 THV using Commander Delivery System.

    Treatment: Edwards Alterra Adaptive Prestent with SAPIEN 3 THV

  • TPVR - PDS RegistryTreatment being tested

    Implantation of Edwards Alterra Adaptive Prestent and Edwards SAPIEN 3 THV using Pulmonic Delivery System (PDS).

    Treatment: Edwards Alterra Adaptive Prestent with SAPIEN 3 THV

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Multicenter Study of Congenital Pulmonic Valve Dysfunction Studying the SAPIEN 3 THV With the Alterra Adaptive Prestent
Record updated
20 October 2026